Is Kronos Bio, Inc. (KRON) a Buy, Sell, or Hold?
Kronos Bio, Inc.
NASDAQ:KRON
$0.9908 USD
$0.01 (1.22%)
- Volume
- 178.58K
- Average Volume
- 316.4K
- Market Capitalization
- $59.79M
- P/E Ratio
- -0.70
- Dividend Yield
- 0.00%
- Price Target
- $1.00
- Year High
- $1.60
- Year Low
- $0.69
- Payout Ratio
- $0.00
- Current Ratio
- $8.32
Industry, Sector & symbol
| Stock Exchange | NASDAQ Global Select |
| CEO | Dr. Norbert W. Bischofberger Ph.D. |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | KRON |
| CUSIP | 50107A104 |
| CIK | 0001741830 |
| Web | https://kronosbio.com |
| Phone | 650 781 5200 |
| Currency | USD |
| Employees | 58 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.23 |
| Payout Ratio | 0.00 |
| Current Ratio | 8.32 |
| Quick Ratio | 8.32 |
| Cash Ratio | 4.87 |
Sales & Book Value
| Annual Sales | $6.29M |
| Price / Sales | 6.06 |
| Cash Flow | -1.29 |
| Price / Cash Flow | -0.77 |
| Price / Book | 0.54 |
Price Target and Rating
| Average Stock Price Forecast | $1.00 |
| High Stock Price Forecast | $1.00 |
| Low Stock Price Forecast | $1.00 |
| Forecast Upside/Downside | -0.92% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 5 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.95 |
| Trailing P/E Ratio | -0.70 |
| PEG Ratio | -0.04 |
| P/E Growth | -0.04 |
| Net Income | $-112.67M |
| Net Margin | -867.66% |
| Pretax Margin | -867.66% |
| Return on Equity | -64.55% |
| Return on Assets | -57.05% |
Financials Score
| AltmanZ Score | -5.15 |
| Piotroski Score | 4.00 |
| Working Capital | 112.54M |
| Total Assets | 150.02M |
| Ebit | -78.49M |
| Market Cap | 59.79M |
| Total Liabilities | 38.9M |
Poll Results
About Kronos Bio, Inc. (NASDAQ:KRON) Stock
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company w ... as incorporated in 2017 and is headquartered in San Mateo, California.
Kronos Bio Announces CEO Transition and Reduction in Force
2024-11-27 07:30:00
– Norbert Bischofberger, Ph.D., is stepping down from his role as President & CEO – – Deborah Knobelman, Ph.D.
2024-11-14 16:02:00
– Preclinical data demonstrate the ability of p300 KAT inhibition to modulate multiple pro-inflammatory signaling pathways, including antibodies and cytokine production, in ex vivo and in vivo models at well tolerated exposures –
Kronos Bio downgraded to Neutral from Overweight at Piper Sandler
2024-11-13 18:36:03
Piper Sandler analyst Edward Tenthoff downgraded Kronos Bio to Neutral from Overweight with a price target of $1, down from $6.
Kronos Bio, Inc. (KRON) Reports Q3 Loss, Tops Revenue Estimates
2024-11-13 18:31:14
Kronos Bio, Inc. (KRON) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.54 per share a year ago.
2024-10-23 08:55:00
– Preclinical data demonstrate that inhibiting the p300 KAT domain reactivates p53 in HPV-driven tumors resulting in anti-tumor activity – – Preclinical data demonstrate that inhibiting the p300 KAT domain reactivates p53 in HPV-driven tumors resulting in anti-tumor activity –
Frequently Asked Questions
-
What is the current Kronos Bio, Inc. (KRON) stock price?
-
Kronos Bio, Inc.(NASDAQ:KRON) stock price is $0.9908 in the last trading session. During the trading session, KRON stock reached the peak price of $1.6 while $0.69 was the lowest point it dropped to. The percentage change in KRON stock occurred in the recent session was 1.22% while the dollar amount for the price change in KRON stock was $0.01.
-
KRON's industry and sector of operation?
-
The NASDAQ listed KRON is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of KRON?
-
Dr. Elizabeth A. Olek D.O., M.P.H. | Senior Vice President of Clinical Development
Dr. Deborah A. Knobelman Ph.D. | Chief Operating Officer & Chief Financial Officer
Dr. Charles Lin Ph.D. | Chief Scientific Officer
Dr. Margaux Bennett Ph.D. | Vice President of Corporate Development & Investor Relations
Mr. David M. Tanen J.D. | Secretary & Director -
How many employees does KRON have?
-
Number of KRON employees currently stands at 58. KRON operates from 1300 South El Camino Real, San Mateo, CA 94402, US.
-
Link for KRON official website?
-
Official Website of KRON is: https://kronosbio.com
-
How do I contact KRON?
-
KRON could be contacted at phone #650 781 5200 and can also be accessed through its website. KRON operates from 1300 South El Camino Real, San Mateo, CA 94402, US.
-
How many shares of KRON are traded daily?
-
The average number of KRON shares traded daily for last 3 months was 316.4K.
-
What is the market cap of KRON currently?
-
The market value of KRON currently stands at $59.79M with its latest stock price at $0.9908